Security key
501575104
Kymera Therapeutics, Inc. - Common Stock (KYMR)
CUSIP: 501575104
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 78,801,021
- Total 13F value
- $3,438,754,240
- Share change
- +5,986,029
- Put/Call ratio
- 36%
- SEC-reported price per share
- $43.64
- Number of holders
- 208
- Value change
- +$270,821,262
- Number of buys
- 131
- Number of sells
- 76
- Shares outstanding
- 82,580,091
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
208
Top holders
10
KYMR full security history
Ownership snapshot
Full 13F holder table
Kymera Therapeutics, Inc. SEC filings
Kymera Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of KYMR - Kymera Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Atlas Venture Fund X, L.P.
Disclosed value leader
Atlas Venture Fund X, L.P.
Comparable rows
0/15
Latest evidence
31 Mar 2025
3/4/5
13F
Highest disclosed value: $235,830,130
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Atlas Venture Fund X, L.P. has the largest disclosed position value at $235.83M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Atlas Venture Fund X, L.P.'s linked filing trail.
Disclosed position value
Top 5
Atlas Venture Fund X, L.P.
$235.83M
ATLAS VENTURE ASSOCIATES X, L.P.
$173.16M
PRICE T ROWE ASSOCIATES INC /MD/
$183.45M
Avoro Capital Advisors LLC
$176.81M
WELLINGTON MANAGEMENT GROUP LLP
$164.13M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Atlas Venture Fund X, L.P. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$235,830,130
5,504,905 shares
|
— | 11 Mar 2024 |
| ATLAS VENTURE ASSOCIATES X, L.P. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$173,161,222
5,763,012 shares
|
— | 11 Aug 2021 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
—
denominator unverified
|
$183,448,000
6,702,450 shares
|
— | 31 Mar 2025 |
| Avoro Capital Advisors LLC |
13F
Company
|
—
denominator unverified
|
$176,810,200
6,460,000 shares
|
— | 31 Mar 2025 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
Company
|
—
denominator unverified
|
$164,134,413
5,996,873 shares
|
— | 31 Mar 2025 |
| BAKER BROS. ADVISORS LP |
13F
Company
|
—
denominator unverified
|
$164,108,577
5,995,929 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
208
Shares
78,801,021
Rows available
208
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
171
Q2 2025 holders
208
Holder diff
37
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|